These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9125795)

  • 1. Advances in treatment: immunoglobulin A nephropathy.
    Hogg RJ; Waldo B
    Semin Nephrol; 1996 Nov; 16(6):511-6. PubMed ID: 9125795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fish oil therapy in IgA nephropathy.
    Fung SM; Ferrill MJ; Norton LL
    Ann Pharmacother; 1997 Jan; 31(1):112-5. PubMed ID: 8997477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
    Parinyasiri U; Ong-Ajyooth L; Parichatikanond P; Ong-Ajyooth S; Liammongkolkul S; Kanyog S
    J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of IgA nephropathies: a critical viewpoint].
    Mertens PR; Floege J
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):1010. PubMed ID: 11004914
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment options for IgA nephropathy in adults: a proposal for evidence-based strategy.
    Laville M; Alamartine E
    Nephrol Dial Transplant; 2004 Aug; 19(8):1947-51. PubMed ID: 15161954
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulating the progression in IgA nephropathy.
    Chan JC; Trachtman H
    Nephron Clin Pract; 2006; 104(1):c61-8. PubMed ID: 16741372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgA nephropathy treatment 25 years on: can we halt progression? The evidence base.
    Ballardie FW
    Nephrol Dial Transplant; 2004 May; 19(5):1041-6. PubMed ID: 15102965
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunoglobulin A Nephropathy and Immunoglobulin A Vasculitis.
    Nicoara O; Twombley K
    Pediatr Clin North Am; 2019 Feb; 66(1):101-110. PubMed ID: 30454736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice.
    Strippoli GF; Maione A; Schena FP; Tognoni G; Craig JC
    Am J Kidney Dis; 2009 Jan; 53(1):5-8. PubMed ID: 19101396
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunoglobulin A nephropathy: fish oils and beyond.
    Feehally J
    Curr Opin Nephrol Hypertens; 1996 Sep; 5(5):442-6. PubMed ID: 8937814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approach of patients with IgA nephropathy.
    Goumenos DS; Brown CB
    Ren Fail; 2004 Mar; 26(2):171-7. PubMed ID: 15287202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of IgA nephropathy: status at the end of the millenium.
    Glassock RJ
    J Nephrol; 1999; 12(5):288-96. PubMed ID: 10630691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [IgA nephropathy--pathogenesis, pathophysiology, and therapy].
    Narita I; Goto S; Kondo D; Sakatsume M; Gejyo F
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():397-402. PubMed ID: 16523921
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of IGA nephritis].
    Risler T; Braun N
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):996. PubMed ID: 11004910
    [No Abstract]   [Full Text] [Related]  

  • 15. The course of disease in patients with nephrotic syndrome and IgA nephropathy.
    Mustonen J; Pasternack A; Helin H
    Semin Nephrol; 1987 Dec; 7(4):374-6. PubMed ID: 3445019
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
    Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early treatment of IgA nephritis is indicated by prognostic factors].
    Barth C
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):1009. PubMed ID: 11004913
    [No Abstract]   [Full Text] [Related]  

  • 18. An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism.
    Strippoli GF; Manno C; Schena FP
    Am J Kidney Dis; 2003 Jun; 41(6):1129-39. PubMed ID: 12776264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.
    Hogg RJ; Lee J; Nardelli N; Julian BA; Cattran D; Waldo B; Wyatt R; Jennette JC; Sibley R; Hyland K; Fitzgibbons L; Hirschman G; Donadio JV; Holub BJ;
    Clin J Am Soc Nephrol; 2006 May; 1(3):467-74. PubMed ID: 17699247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.
    Hogg RJ; Fitzgibbons L; Atkins C; Nardelli N; Bay RC;
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1167-72. PubMed ID: 17699343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.